Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enhabit, Inc. filings document formal disclosures for a public home health and hospice care provider. Recent reports include 8-K material-event disclosures, Regulation FD materials, operating and financial results, risk-factor updates, shareholder voting matters and capital-structure information.
The company’s SEC record also covers material definitive agreements, including credit facilities and related debt terms, governance matters such as officer transitions, and litigation-related disclosures involving claims connected to its home health and hospice business history. These filings frame Enhabit’s regulatory reporting around healthcare operations, financing arrangements, corporate governance and stockholder matters.
Enhabit, Inc. director reports stock-based fee payment
Enhabit, Inc. director Gregory S. Rush reported receiving 2,508 shares of common stock on January 10, 2026. The transaction is coded "A," indicating an acquisition, at a reported price of $9.97 per share. After this grant, he beneficially owns 78,551 shares of Enhabit common stock in direct ownership.
The footnote explains that these 2,508 shares represent deferred stock units taken instead of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan, meaning a portion of his director compensation was elected in equity rather than cash.
Enhabit, Inc. director Erin Hoeflinger reported acquiring 2,382 shares of Enhabit common stock on January 10, 2026. The shares were received as deferred stock units in lieu of a cash retainer fee, under the Enhabit, Inc. Deferred Director Compensation Plan, meaning she chose to take part of her board compensation in stock-based form instead of cash.
The transaction was coded as an acquisition at a price of $9.97 per share, and following this award she beneficially owns 78,707 shares of Enhabit common stock, held directly. This is a routine director compensation-related transaction rather than an open-market trade.
Enhabit, Inc. director Jeffrey Bolton acquired 3,761 deferred stock units on January 10, 2026, elected in lieu of a cash retainer under the Enhabit Deferred Director Compensation Plan. The units are reported as common stock at a reference price of $9.97 per share, and following this grant he beneficially owns 137,002 shares directly.
Enhabit, Inc. Chief Financial Officer reported a disposition of company common stock in a Form 4 filing. On 12/09/2025, 21,777 shares of common stock were used at a price of $9.60 per share to satisfy withholding taxes due upon the vesting of equity awards. Following this tax-withholding transaction, the reporting person beneficially owns 171,691 shares of Enhabit common stock.
Enhabit, Inc. filed a report stating that it will participate in the BofA Securities 2025 Home Care Conference on December 9, 2025, at 2:50 p.m. CT. President and CEO Barbara Jacobsmeyer and Chief Financial Officer Ryan Solomon will take part in a fireside chat.
They intend to discuss Enhabit’s strategic focus, recent business developments, and an update to anticipated pricing impacts for 2026, among other topics. An investor presentation supporting this discussion has been made available as Exhibit 99.1 and is incorporated by reference, though it is being furnished rather than filed, which limits its use for certain legal purposes.
Enhabit (EHAB) reported a return to profitability in Q3 2025. Net service revenue was $263.6M, up 3.9% year over year. Operating income reached $16.8M versus a loss in the prior year, and net income attributable to Enhabit was $11.1M, or $0.22 per diluted share, compared with a loss of $110.2M a year ago, which included a goodwill impairment.
Hospice drove the quarter with revenue of $63.1M, up 20.0%, while Home Health was $200.5M, down 0.2%. Adjusted EBITDA was $27.0M versus $24.5M. For the first nine months, revenue was $789.6M (up 1.7%) and net income was $34.1M, helped by a $19.3M gain on sale of an investment. Interest expense fell with lower borrowings and rates.
Cash rose to $56.9M, and total debt was $463.8M, including $333.5M on the term loan and $125.0M drawn on the revolver. The company closed or consolidated 13 branches year‑to‑date and remained in compliance with credit facility covenants. CMS finalized a 2.6% hospice payment increase effective October 1, 2025, and proposed a 6.4% home health decrease for 2026.
Enhabit, Inc. furnished an 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025. The company also provided supplemental materials for its earnings discussion.
Exhibit 99.1 contains the earnings press release dated November 5, 2025, and Exhibit 99.2 includes supplemental information for the third quarter 2025 earnings call. The call is scheduled for 9:00 a.m. Eastern Time on Thursday, November 6, 2025. The materials under Items 2.02 and 7.01 are being furnished, not filed.
Enhabit, Inc. (EHAB) director Erin Hoeflinger purchased 2,969 shares of the company's common stock on 10/10/2025 at a price of $8 per share. After the transaction the reporting person beneficially owned 76,325 shares. The Form 4 was filed as an individual filing and is signed by an attorney in fact.
Enhabit, Inc. (EHAB) filed a Form 4 reporting a director’s share acquisition. On 10/10/2025, the reporting person acquired 2,969 shares of common stock at a price of $8 per share. Following this transaction, the filer beneficially owns 67,850 shares. Ownership is reported as direct.
Stuart M. McGuigan, a director of Enhabit, Inc. (EHAB), reported a purchase of 2,344 shares of the company's common stock on 10/10/2025 at a price of $8 per share. After the transaction he beneficially owns 72,245 shares. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact, Sarah W. Braley, on 10/10/2025. The filing discloses a routine insider purchase by a board member with no derivative transactions reported.